Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Contributed by: PR Newswire

Tags

Camurus

More Like This

PR Newswire associated0

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

Camurus reports positive topline results for CAM2056, semaglutide monthly depot

Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

PR Newswire associated0

Amacathera Collaborates With Leading Global Pharmaceutical Company To Develop Single-Injection, Long-Acting Biologic Using Its Advanced Hydrogel Delivery Platform, Amacagel™

Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing